netFormulary South East London Joint Medicines Formulary NHS
Guy's and St Thomas' NHS Foundation Trust
Kings College Hospital NHS Foundation Trust
Lewisham and Greenwich NHS Trust
 
 Search
 Formulary Chapter 6: Endocrine system - Full Chapter
Notes:

Where a formulary entry does not detail a medicine’s indications for use, the medicine can be assumed to be approved for all licensed indications.

Formulary approved "off-label" use is detailed separately.

Chapter Links...
 Details...
06.01.02.03  Expand sub section  Other antidiabetic drugs
06.01.02.03  Expand sub section  Alpha glucosidase inhibitors
06.01.02.03  Expand sub section  GLP-1 mimetics
06.01.02.03  Expand sub section  DPP4 inhibitors (gliptins)
06.01.02.03  Expand sub section  SGLT2 inhibitors to top
Canagliflozin tabs
View adult BNF View SPC online
Formulary
Green
 
Link  MHRA Advice - SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis, April 2016
Link  MHRA Mar 2017: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation
Link  NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
   
Dapagliflozin tabs (type 1 diabetes)
View adult BNF View SPC online
Formulary
Red

Approved as per NICE technology appraisal guidance (see link below)

Specialist diabetologist recommendation only

Currently for hospital prescribing only.  Formal ongoing supply arrangements being reviewed by the APC.

 
Link  MHRA Apr 2016: SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis
Link  MHRA Mar 2017: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)
Link  NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes
   
Dapagliflozin tabs (type 2 diabetes)
View adult BNF View SPC online
Formulary
Green

Approved as per NICE technology appraisal guidance (see links below)

 
Link  MHRA Advice - SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis, April 2016
Link  MHRA Mar 2017: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation
Link  NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Link  NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
   
Empagliflozin tabs
View adult BNF View SPC online
Formulary
Green
 
Link  MHRA Advice - SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis, April 2016
Link  MHRA Mar 2017: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation
Link  NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
Link  NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
   
Ertugliflozin tabs
View adult BNF View SPC online
Formulary
Green

 

 
Link  MHRA Advice - SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis, April 2016
Link  MHRA Mar 2017: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation
Link  NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Link  NICE TA583:Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
   
Sotagliflozin tabs (type 1 diabetes)
View adult BNF View SPC online
Formulary
Red

Approved as per NICE technology appraisal guidance (see links below)

 
Link  NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes
   
06.01.02.03  Expand sub section  Meglitinides
06.01.02.03  Expand sub section  SGL2 inhibitors
06.01.02.03  Expand sub section  Other
06.01.02.03  Expand sub section  Thiazolidinediones
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Specialist or hospital prescribing only. The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital. In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.   

Amber 1

Treatment can be initiated in primary care after a recommendation from an appropriate specialist  

Amber 2

Specialist initiation followed by maintenance prescribing in primary care  

Amber 3

Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation  

Green

Specialist and non-specialist initiation  

Grey

Not recommended for prescribing  

netFormulary